Mostefa B.
- Country
- France
- Department
- Oncologie médicale
Research Overview
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- Evaluation of Pembrolizumab and Axitinib Combination Versus Sunitinib Monotherapy in First-line Treatment of Metastatic Renal Cell Carcinoma
Data & Insights
Has run more than one trial at 76 of 239 partner sites.
Specializations
Urological Oncology
The investigator specializes in treating various forms of bladder cancer, including muscle-invasive bladder cancer (MIBC) and non-muscle invasive bladder cancer (NMIBC). Their research extends to advanced therapeutic approaches for urothelial carcinoma in both locally advanced and metastatic stages.
- Bladder Cancer Management
- Urothelial Carcinoma Treatment
- Novel Therapeutic Combinations
Prostate Cancer Research
The investigator focuses on treating various stages of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC) and hormone-sensitive prostate cancer. They have expertise in managing localized prostate cancer with high-risk features and innovative treatment approaches.
- Advanced Prostate Cancer Therapy
- Hormone-Sensitive Disease Management
- High-Risk Disease Treatment
Kidney Cancer Treatment
The investigator has significant experience in treating renal cell carcinoma across various stages, including metastatic disease. Their work encompasses both adjuvant therapy approaches and treatment strategies for metastatic kidney cancer.
- Renal Cell Carcinoma Management
- Advanced Kidney Cancer Treatment
- Targeted Therapeutic Approaches
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.